Comparative safety of sulfonylureas and the risk of sudden cardiac arrest and ventricular arrhythmia Academic Article uri icon

Overview

MeSH Major

  • Bias (Epidemiology)
  • Confounding Factors (Epidemiology)
  • Data Interpretation, Statistical
  • Outcome Assessment (Health Care)
  • Research Design

abstract

  • Glyburide may be associated with a lower risk of SCA/VA than glipizide, consistent with a very small clinical trial suggesting that glyburide may reduce ventricular tachycardia and isolated ventricular premature complexes. This potential benefit must be contextualized by considering putative effects of different sulfonylureas on other cardiovascular end points, cerebrovascular end points, all-cause death, and hypoglycemia.

publication date

  • April 2018

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5860838

Digital Object Identifier (DOI)

  • 10.2337/dc17-0294

PubMed ID

  • 29437823

Additional Document Info

start page

  • 713

end page

  • 722

volume

  • 41

number

  • 4